Trevena lands $35M round to fund its first PhII

With its lead drug poised to start a Phase II clinical trial at the beginning of next year, Trevena has raised enough venture funds to fuel its work right through the proof-of-concept stage. New Enterprise Associates and Polaris Venture Partners led the round, with all other existing Trevena investors--Alta Partners, Healthcare Ventures and Yasuda Economic Development Corporation--chipping in to a $35 million round. Armed with knowledge on GPCR-targeting biased ligands developed in the labs of...